On June 29, 1995, a 49-year-old man was admitted with acute onset of fever, petechiae on his legs, and mental confusion He had suffered hypertension since 6 months previously and was on nicardipine (60 mg/day), ifenprodil (60 mg/day) and ticlopidine (300 mg/day). He had been on ticlopidine for 4 weeks and on the other drugs for 6 months. Soon after admission he had frequent grand mal seizures and needed mechanical ventilation. A diagnosis of TTP was made. He was treated with plasmapheresis (50 ml/kg per day), aspirin 81 mg/day and dipyridamole 300 mg/day. On the sixth day his mental status returned to normal. He recovered gradually from microangiopathic hemolytic anemia, thrombocytopenia and elevated serum creatinine. We reviewed the literature and discussed the possible mechanism of TTP related to the use of ticlopidine.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Randomized evaluation of the loss-of-function carboxylesterase 1 (CES1) G143E variant on clopidogrel and ticagrelor pharmacodynamics.
Clin Transl Sci
November 2024
Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Article Synopsis
- Antiplatelet therapy, particularly with P2Y receptor inhibitors alongside aspirin, is essential for treating coronary artery disease, and different medication options can help tailor patient care.
- A study investigated the effects of a specific genetic mutation (G143E in CES1) on the effectiveness of clopidogrel and ticagrelor in inhibiting platelet aggregation in patients.
- Results showed that the G143E mutation significantly affected platelet response to clopidogrel, but not to ticagrelor, indicating ticagrelor may provide more consistent treatment for patients with clopidogrel response-altering genetics.
Impact of Multiarterial versus Single Arterial Coronary Bypass Graft Surgery on Postoperative Atrial Fibrillation.
Am J Cardiol
January 2025
Department of Cardiac Surgery, Fuwai Hospital, Beijing, China.
The effect of multiarterial (MA) versus single arterial (SA) coronary bypass graft surgery on postoperative atrial fibrillation (POAF) was not investigated. From May 2017 to May 2024, the patients with CYP2C19*2 or *3 allele receiving coronary artery grafting and postoperational aspirin 100 mg/day and clopidogrel 75 mg/day were retrospectively reviewed and assigned to the MA or SA group. The primary end point was the incidence rate of POAF in the first week.
View Article and Find Full Text PDFA retrospective study of the safety and efficacy of clopidogrel versus aspirin monotherapy one year after coronary stent implantation.
BMC Pharmacol Toxicol
September 2024
Department of Cardiology, Jinshan Hospital of Fudan University, Shanghai, 201500, China.
Background: The ideal single antiplatelet therapy for long-term maintenance after coronary stenting remains uncertain. In a head-to-head comparison, we aimed to evaluate the efficacy and safety profile of aspirin and clopidogrel as monotherapies in this patient cohort.
Method: We reviewed 1044 patients who underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES) at the Department of Cardiovascular Medicine, Jinshan Hospital of Fudan University, between January 2019 and December 2021 and completed a 12-month Dual Antiplatelet Therapy (DAPT) treatment.
Association of CYP2C19 genotypes with postoperative atrial fibrillation after coronary artery bypass surgery.
Clin Transl Sci
June 2024
Department of Cardiac Surgery, Fuwai Hospital, Beijing, China.
This cohort study aims to assess the connection between cytochrome P450 family 2 subfamily C member 19 (CYP2C19) genotyping, platelet aggregability following oral clopidogrel administration, and the occurrence of postoperative atrial fibrillation (POAF) after off-pump coronary artery bypass graft (CABG) surgery. From May 2017 to November 2022, a total of 258 patients undergoing elective first-time CABG surgery, receiving 100 mg/day oral aspirin and 75 mg/day oral clopidogrel postoperatively, was included for analysis. These patients were categorized based on CYP2C19 genotyping.
View Article and Find Full Text PDFOne-Month Dual Antiplatelet Therapy Followed by P2Y Inhibitor Monotherapy After Biodegradable Polymer Drug-Eluting Stent Implantation - The REIWA Region-Wide Registry.
Circ J
May 2024
Division of Cardiology, Department of Internal Medicine, Iwate Medical University.
Background: The safety and feasibility of using 1-month dual antiplatelet therapy (DAPT) followed by P2Yinhibitor monotherapy for patients after percutaneous coronary intervention (PCI) with thin-strut biodegradable polymer drug-eluting stents (BP-DES) in daily clinical practice remain uncertain.
Methods and results: The REIWA region-wide registry is a prospective study conducted in 1 PCI center and 9 local hospitals in northern Japan. A total of 1,202 patients who successfully underwent final PCI using BP-DES (Synergy: n=400; Ultimaster: n=401; Orsiro: n=401), were enrolled in the registry, and received 1-month DAPT followed by P2Yinhibitor (prasugrel 3.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!